Clinical

Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis.

Sickle cell disease (SCD) will be the first focus of the Cell and Gene Therapy (CGT) Access Model; the FTC has challenged the validity of over 100 drug product patents to help increase competition and potentially lower prices; the rate of infectious syphilis cases in the US rose 9% in 2022.

However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and became statistically insignificant after adjusting for cumulative past LDL-C exposure.

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).

Elevated serum vitamin B12 concentration was positively associated with all-cause mortality risk, particularly among older adults, with concentrations exceeding 400 pmol/L showing significantly higher mortality rates.

Since 1987, only 57 cases of comorbid Parkinson disease (PD) and myasthenia gravis (MG) have been reported.

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.

The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.

Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.

Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.

A key opinion leader explores the integration of bispecifics into MM therapy regimens.

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

Key opinion leaders explore the necessary synergy between payors and providers for optimizing bispecific therapy.

Financial considerations in bispecific therapy are discussed.

Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.

The data search of Web of Science Core Collection, spanning 2003 to 2022, identified various prospective directions in myasthenia gravis (MG) research, including in personalized treatment, subtype-based treatment, and novel immunotherapeutic strategies.

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

US women in low-income regions are experiencing a steep increase in cervical cancer diagnosis and death despite medical improvements; a Senate committee launches an assisted living examination, its first hearing on the industry in 2 decades; the CDC urges health care providers to be alert for patients who have fever, rashes, an traveled abroad following reports of 23 measles cases since December 1.

The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.

The critical impact of respiratory and physical therapists in the management of bronchiectasis is emphasized.

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).

Researchers found TET2 clonal hematopoiesis of indeterminate potential (CHIP) to be an independent risk factor associated with incident heart failure with preserved ejection fraction (HFpEF).

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.